ATS to gain $13 million from shares sale:
This article was originally published in Clinica
ATS Medical is to sell approximately 3.7 million shares of common stock at $3.55 per share to certain institutional investors. The sale is expected to earn Minneapolis, Minnesota-based ATS $13.1m. The developer of heart valves and cardiovascular instruments plans to use the proceeds for general working capital purposes and to finance the manufacturing of its ATS open pivot valve, which, according to the company, has been implanted in over 85,000 patients. Some of the funds will also be used for the introduction of the PARSUS blood filtration technology for which ATS recently acquired worldwide rights from Swedish firm ErySave (see Clinica No 1106, p 24).
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.